

## Detailed Table of Contents

### Chapter 1 Disease Definition and Overview of Pathogenesis of

<b>Hyperuricemia and Gouty Inflammation</b> .....	15
Definitions.....	15
Gout.....	15
Hyperuricemia.....	18
Uric Acid Metabolism and Pathogenesis of Hyperuricemia.....	22
Overall Effects of Inherited Genetic Variants on Hyperuricemia and Gout and Response to Allopurinol.....	23
Impaired Renal Elimination of Uric Acid.....	38
Increased Uric Acid Production.....	39
Uric Acid Production as a Target of Therapy in Patients With Gout.....	43
Pathogenesis of Tissue Deposition of Urate Crystals Into Tophi.....	43
Pathogenesis of Acute Gouty Inflammation.....	45
Take-Away Messages.....	51
<b>Chapter 2 Who Gets Gout?</b> .....	57
Epidemiology of Gout and Hyperuricemia.....	57
Heritability of Gout.....	58
Increasing Gout Prevalence and Complexity.....	59
Comorbidity and Medication-List Worksheet for Gout and Hyperuricemia.....	64
Antihypertensive Medications and Gout.....	66
Hyperuricemia and Comorbidities.....	67
Health Care Utilization and Financial Impact of Gout.....	70
Take-Away Messages.....	71
<b>Chapter 3 Clinical Features and Natural Course</b> .....	83
Asymptomatic Hyperuricemia.....	83
Acute Intermittent Gout.....	84
Advanced Gout.....	88
Nonclassic Presentations of Gouty Arthritis.....	92
Early-Onset Gout.....	92
Gout in Women.....	92
Gout and Major Organ Transplant.....	93
Acute Polyarticular Gout.....	93
Axial Skeletal Gout.....	93
System Urate Deposition.....	94
Clinical Presentations of Renal Disease With Gout and Hyperuricemia.....	95
Take-Away Messages.....	96
<b>Chapter 4 Diagnosis of Gout and Use of Laboratory and Imaging</b> .....	101
When There is Reasonable Doubt About the Diagnosis of Acute or Chronic Gouty Arthritis, the Gold Standard is to Aspirate the Joint for Diagnosis.....	102
Differential Diagnosis of Gout.....	104
Infectious (Septic) Arthritis.....	104
Pseudogout.....	104
Osteoarthritis.....	104
Posttraumatic Arthritis or Soft Tissue Injury.....	105
Spondyloarthropathy.....	107
Bacterial Cellulitis.....	108

RA.....	108
Lyme Disease.....	108
How to Integrate Clinical, Lab, and Imaging Information to Support and Establish the Diagnosis of Gout.....	108
The Gold Standard for Diagnosis of Acute Gout is Most Frequently Not Performed.....	108
Limitations of Existing Formal Criteria for Diagnosis of Acute Gout.....	109
2016 Agency for Healthcare Research and Quality (AHRQ) Assessment of Gout Diagnosis Criteria.....	110
How the Authors of this Handbook Assess Best Use of Existing Clinical Gout Diagnostic Criteria.....	111
Use of the Laboratory to Analyze Synovial Fluid in Diagnosis of Gout.....	111
Examination of Joint Fluid.....	114
Synovial Fluid Crystal Analysis by Compensated Polarized Light Microscopy.....	114
Imaging of Gout.....	117
High-Resolution Ultrasound: A particularly Useful Approach for Early Disease in Gout and in Differential Diagnosis.....	118
Dual Energy CT (DECT) and Comparison to the Alternative Options of Ultrasound, CT, and MRI Imaging of Gout.....	124
Take-Away Messages.....	137
<b>Chapter 5 Synopsis and Assessment of the 2015 Gout Classification Criteria</b> .....	145
Take-Away Messages.....	146
<b>Chapter 6 Management of Acute Gouty Arthritis</b> .....	165
Principal Goals of Treatment.....	165
Choice of Treatment Regimens.....	167
Factors in Selecting the Gouty Arthritis Treatment Regimen for the Individual Patient.....	167
NSAIDs and COX-2-Selective Inhibitors.....	171
Systemic Corticosteroids.....	173
Oral Therapy.....	173
Parenteral Systemic Corticosteroid Therapy.....	175
Rebound Flares of Gout After Discontinuation of Systemic Corticosteroids.....	175
Colchicine.....	175
Mechanism of Action.....	175
Best Practice for Use of Colchicine in Acute Gout.....	176
Dosing Guidelines for Acute Gout.....	176
Colchicine Side Effects in the Treatment of Acute Gout.....	180
Intra-articular Corticosteroids.....	181
ACTH.....	181
Canakinumab.....	185
Combinations of Therapies.....	186
Other Modalities.....	186
Emerging Treatments.....	186
Treatment of Pseudogout.....	187
Take-Away Messages.....	187
<b>Chapter 7 Approach to Diet, Alcohol, and Other Lifestyle Factors in the Treatment of the Patient With Gout and Hyperuricemia</b> .....	193

Alcohol and Diet.....	194	Practical Points About Patient Education and Simplified Informational Materials That Can Be Given to Gout Patients ..	287
Alcohol.....	194	Take-Away Messages.....	293
Sugar and the Particular Effects of Fructose.....	195	<b>Chapter 11 Comprehensive Disease-Management Plan</b>	
Total Carbohydrate Quality, Quantity, and the Glycemic Index ..	201	<b>for Gout</b> .....	295
Omega-3 Fatty Acids.....	203	Acute Gout Management.....	298
Soy .....	203	Initiating ULT and Use of Gout-Flare Prophylaxis .....	300
Coffee and Caffeine.....	203	Reaching the Target Serum Urate Level .....	302
Cigarettes.....	204	Take-Away Messages.....	302
Dairy Products.....	204	<b>Chapter 12 Difficult Gout and Hyperuricemia: Therapeutic</b>	
Ascorbate .....	204	<b>Strategies and Options</b> .....	307
Cherry Products .....	205	Gout in Elderly Individual .....	307
Other Factors .....	206	Gout in CKD: How to Define and Assess CKD and Choose Gout Therapies in CKD.....	310
Obesity, Physical Fitness, and Hyperuricemia and Gout.....	206	Defining the Stage of CKD .....	310
Overall Dietary and Lifestyle Strategy and Expectations for Management of Patients With Gout .....	207	ULT and Predominant Role of Xanthine Oxidase Inhibitors (XOI) in Gout Patients With Stage 3 CKD.....	310
How to Advise the Gout Patient on Dietary and Alcohol .....	208	NSAID and Colchicine Use in Gout Patients With Renal Disease .....	313
Take-Away Messages.....	208	Gout Therapy Consideration in ESRD and Hemodialysis.....	313
<b>Chapter 8 Pharmacologic Urate-Lowering Therapy</b> .....	215	Refractory Acute Gout .....	314
Indications and Goals of ULT .....	215	Refractory Hyperuricemia in Management of Chronic Gout.....	315
Urate-Lowering Drugs.....	218	Uricosuric “Add-On” Therapy to XOI Treatment of Refractory Hyperuricemia in Nontophaceous and Tophaceous Gout.....	315
Allopurinol.....	219	Investigational Oral Agents for Treatment of Refractory Hyperuricemia in Gout .....	318
How Allopurinol Should be Dosed for Prevention of Severe Allopurinol Hypersensitivity Reaction .....	222	Intravenous Biologic Pegloticase Therapy in Treatment- Refractory Chronic Gout .....	319
Febuxostat.....	225	Gout in Association With Major Organ Transplantation .....	323
Probenecid .....	237	Take-Away Messages.....	329
Pegloticase.....	239	<b>Chapter 13 The 2020 American College of Rheumatology</b>	
Urate-Lowering Agents in Development.....	245	<b>Guidelines for the Management of Gout</b> .....	335
Urate-Lowering Strategy.....	247	Indications for Pharmacologic ULT.....	336
Take-Away Messages.....	247	Recommendations for Choice of Initial ULT for Patients with Gout .....	336
<b>Chapter 9 Prophylaxis of Acute Gout Flares</b> .....	255	Recommendations for All Patients Receiving ULT .....	339
Nonpharmacologic Approaches: Importance of Diet and Alcohol Moderation and of Hydration in Preventing Flares.....	260	Recommendations for the Use of Specific ULT Agents.....	341
Precipitation of Gout Flares by ULT .....	261	When to Consider Changing ULT Strategy.....	343
Best-Practice Guidelines on Starting and Terminating Gout- Flare Prophylaxis When Initiating ULT .....	264	Gout Flare Management .....	345
Colchicine in Gout Flare Prophylaxis .....	264	Management of Lifestyle Factors .....	345
Evidence Basis for Colchicine in Flare Prophylaxis .....	264	Management of Concurrent Medications .....	348
Colchicine Dosing Guidelines for Gout-Flare Prophylaxis.....	267	The Treat-to-Target Divergence between the 2020 ACR Guidelines and the 2016 American College of Physicians (ACP) Guidelines.....	348
Side Effects of Low-Dose Colchicine in Gout-Flare Prophylaxis Therapy .....	267	Comparison of the 2020 ACR Guidelines with the 2016 EULAR Guidelines .....	350
Dosing of Prophylactic Colchicine With Age and Renal Impairment and Standard Use of CK and Hemogram to Monitor for Toxicity.....	268	<b>Chapter 14 Improving Quality of Gout Management</b>	
Understanding Colchicine Clinical Pharmacology to Avoid Drug-Drug Interactions .....	269	<b>in Primary Care</b> .....	353
Colchicine and Cardiovascular Event Prevention.....	272	Quality of Care Gaps in Gout .....	353
Low-Dose NSAID Prophylaxis of Gout Flares.....	276	Take-Away Messages.....	359
Other Pharmacologic Approaches for Gout-Flare Prophylaxis .....	277	<b>Chapter 15 Abbreviations/Acronyms</b> .....	363
Approaches Under Investigation.....	277		
Take-Away Messages.....	279		
<b>Chapter 10 The Critical Importance of Patient</b>			
<b>Education in Gout</b> .....	285		
Educational Barriers to the Optimal Management of Gout .....	286		